What is the recommended long‑term pharmacologic prophylaxis and dosing for a hemodynamically stable adult with recurrent paroxysmal supraventricular tachycardia and no structural heart disease?

Long-Term Pharmacologic Prophylaxis for Recurrent Paroxysmal SVT

For hemodynamically stable adults with recurrent paroxysmal supraventricular tachycardia and no structural heart disease, oral beta blockers, diltiazem, or verapamil are first-line agents for long-term prophylaxis, with catheter ablation remaining the preferred definitive therapy. 1

First-Line Pharmacologic Options (Class I Recommendation)

The ACC/AHA/HRS guidelines provide Class I (highest level) recommendations for three medication classes as initial long-term therapy 1:

Beta Blockers

• Metoprolol tartrate: 25 mg twice daily, titrate up to maximum 200 mg twice daily 2
• Alternative beta blockers include propranolol (240 mg/day), atenolol, or nadolol 1, 2
• Beta blockers are effective in reducing both frequency and duration of SVT episodes 1, 3
• Preferred when calcium channel blockers are contraindicated, particularly in systolic heart failure 3, 2

Calcium Channel Blockers (Nondihydropyridine)

• Verapamil: 360-480 mg/day (randomized trials demonstrate reduction in episode frequency and duration) 1
• Diltiazem: standard dosing (similar efficacy to verapamil) 1
• A small randomized trial showed verapamil at 480 mg/day had similar efficacy to propranolol 240 mg/day and digoxin 0.375 mg/day 1

Digoxin (Less Preferred First-Line)

• Digoxin: 0.375 mg/day 1
• Modest efficacy compared to beta blockers and calcium channel blockers 2
• Reserved for patients who cannot tolerate or have contraindications to other first-line agents 1

Second-Line Agents: Class Ic Antiarrhythmics (Class IIa Recommendation)

For patients without structural heart disease or ischemic heart disease who fail AV nodal blocking agents, flecainide or propafenone are the preferred second-line choices 1:

Flecainide

• Starting dose: 50 mg every 12 hours for PSVT 4
• Titration: Increase by 50 mg twice daily every 4 days until efficacy achieved 4
• Usual effective dose: 200-300 mg/day (completely suppresses episodes in 65% of patients) 1
• Maximum dose for paroxysmal supraventricular arrhythmias: 300 mg/day 4
• Steady-state levels require 3-5 days at a given dose due to long half-life (12-27 hours) 4
• Excellent chronic tolerance and safety in patients without structural heart disease 1

Propafenone

• Dose range: 450-900 mg/day 1
• One randomized trial showed 86% probability of 12 months of effective treatment (defined as <2 attacks) 1

Critical Contraindications for Class Ic Agents

Flecainide and propafenone are absolutely contraindicated in patients with: 1, 2

• Structural heart disease
• Ischemic heart disease or coronary artery disease
• Left ventricular dysfunction
• History of myocardial infarction

These agents carry proarrhythmic risk in the above populations and should never be used 1

Third-Line Agents (Class IIb Recommendation - May Be Reasonable)

Sotalol

• Dose: 80 mg or 160 mg twice daily 1
• Class III antiarrhythmic with beta-blocker properties 1
• Can be used in patients with structural heart disease (unlike Class Ic agents) 1
• Randomized trial showed significant reductions in recurrence risk with no proarrhythmic adverse effects 1
• Reserved for patients not candidates for ablation and in whom first-line agents are ineffective 1

Dofetilide

• Class III antiarrhythmic without beta-blocker properties 1
• Reserved for patients in whom beta blockers, diltiazem, flecainide, propafenone, or verapamil are ineffective or contraindicated 1

Amiodarone

• Only as last-resort option due to limited evidence and significant potential toxicity 1, 2
• Reserved for patients in whom all other therapies are ineffective or contraindicated 1
• The ESC downgraded amiodarone for SVT management specifically due to toxicity concerns 2

Agents to Avoid

Class Ia antiarrhythmics (quinidine, procainamide, disopyramide) have limited appeal due to multidosing regimens, modest efficacy, and adverse/proarrhythmic effects 1, 2. These are rarely used for AVNRT today 1.

Treatment Algorithm

1. First, consider catheter ablation (Class I recommendation): Single-procedure success rates of 94.3-98.5% with cure rates >90-95% 1, 3, 5
2. If ablation declined or not a candidate:
   • Start with oral beta blocker, diltiazem, or verapamil 1, 3
   • Choice guided by comorbidities (beta blockers preferred if calcium channel blockers contraindicated) 3, 2
3. If first-line agents fail and no structural heart disease:
   • Add flecainide or propafenone 1
4. If second-line agents fail or contraindicated:
   • Consider sotalol, dofetilide, or amiodarone (in that order) 1

Critical Safety Considerations

Absolute contraindications to AV nodal blocking agents (beta blockers, calcium channel blockers, digoxin): 3, 2

• Pre-excited atrial fibrillation or Wolff-Parkinson-White syndrome with AF/flutter (can precipitate ventricular fibrillation)
• Hemodynamic instability
• Signs of heart failure or pulmonary edema
• Second- or third-degree heart block or PR interval >0.24 seconds
• Active asthma or reactive airways disease (for beta blockers)

Special Populations

Renal Impairment

• Beta blockers require dose reduction in severe renal dysfunction 2
• Flecainide requires dose adjustment in severe renal impairment (creatinine clearance <35 mL/min) 4

Pediatric Patients

• Flecainide dosing in children: Initial 50-100 mg/M² body surface area daily (depending on age), maximum 200 mg/M² per day 4
• All pediatric use should be supervised by a pediatric cardiologist 4

Common Pitfalls

• Do not use loading doses of flecainide - increased incidence of proarrhythmic events and CHF with rapid dosage adjustments 4
• Do not increase flecainide doses more frequently than every 4 days - steady-state levels require 3-5 days 4
• Do not use Class Ic agents without confirming absence of structural heart disease - obtain echocardiogram if not recently performed 1
• Evidence for long-term pharmacotherapy effectiveness is limited compared to catheter ablation 5